Husch Blackwell is pleased to announce partner Don Mizerk has been named to Crain’s Chicago Business’ Notable Litigators and Trial Attorneys list for 2023.
Mizerk was selected for being one of the preeminent generic drug patent litigators in the country. In October 2021 he led a trial team that successfully defended patent litigation against Sigmapharm Laboratories’ generic version of the antidepressant Trintellix® by Takeda Pharmaceutical. In 2021, Trintellix® had U.S. sales of approximately $694 million. Mizerk also led successful defenses of Nanjing Noratech’s generic version of Entresto®, and Handa Pharmaceuticals’ novel orally-disintegrating tablet version of Novartis’ Gilenya, among others.
Mizerk is currently representing Handa Oncology in a case brought by Bristol-Myers Squibb Company involving patents related to Sprycel, a blockbuster $2 billion/year drug for Bristol-Myers Squibb.
In September 2022, Patexia named Husch Blackwell one of the Top 50 firms for its performance on behalf of defendants in ANDA litigation and among the top 100 firms for its performance on behalf of plaintiffs. Mizerk received individual recognition among the most active ANDA attorneys on the defendant side.